Vaxcyte, Inc. PCVX
65.68 USD +4.87 (+8.01%)
At closeNov 4, 2026, 5:04 PM EST
65.68 0.00 0.00%
After hours · Nov 4, 5:04 PM ET
60.04 Day range 65.71
39.87 52-week range 90.75
- YTD
- +42.35%
- 1 year
- +58.84%
News
benzinga.com Vaxcyte Q3 EPS $(1.99) Beats $(2.12) Estimate Vaxcyte (NASDAQ:PCVX) reported quarterly losses of $(1.99) per share which beat the analyst consensus estimate of $(2.12) by 6.13 percent. This is a 27.56 percent decrease over losses of $(1.56) per…
globenewswire.com Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update VAX-31 Adult Indication: Announced Positive Topline Data from OPUS-1 Pivotal Phase 3 Trial; VAX-31 Met All Prespecified Primary Endpoints, Was Well Tolerated and Demonstrated a Safety Profile Similar…
zacks.com Wall Street Analysts See an 87.35% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High? The mean of analysts' price targets for Vaxcyte (PCVX) points to an 87.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among…
defenseworld.net Vaxcyte, Inc. (NASDAQ:PCVX) Stock Rated “Moderate Buy” by Sell-Side Brokerages Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine brokerages that are currently covering the stock, Marketbeat.com reports.…
zacks.com Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet The average of price targets set by Wall Street analysts indicates a potential upside of 75.6% in Vaxcyte (PCVX). While the effectiveness of this highly sought-after metric is questionable, the…
benzinga.com Cantor Fitzgerald Reiterates Overweight on Vaxcyte, Announces $120 Price Target Cantor Fitzgerald analyst Carter Gould reiterates Vaxcyte (NASDAQ:PCVX) with a Overweight and announces $120 price target.
benzinga.com Stephen King Slams Trump’s New Press Secretary as Past Vaccine Conspiracy Theories, Third-Term Posts Spark Fresh Controversy: 'She Appears to Have Tried to…' Stephen King slammed Trump’s incoming press secretary over her vaccine conspiracy theories and controversial posts.
defenseworld.net Vaxcyte (NASDAQ: PCVX) raises $575 million with notes and stock sale What happened Vaxcyte, Inc. (NASDAQ: PCVX) closed a financing on October 9, 2026, and sold $575 million of 1.50% convertible senior notes due 2032. The notes are senior unsecured obligations. The…
benzinga.com A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally A new NIH-backed initiative to speed up personalized cancer vaccine development sent stocks like MRNA, BNTX, and NVAX surging Friday.
defenseworld.net Vaxcyte (NASDAQ:PCVX) EVP Jim Wassil Sells 18,000 Shares of Company Stock Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) EVP Jim Wassil sold 18,000 shares of the company's stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $86.74,…
globenewswire.com Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes SAN CARLOS, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of concurrent underwritten public…
seekingalpha.com Vaxcyte: 'Strong Buy' On VAX-31 Trial Win IPD VAX-31 And Additional Readouts 1st Half 2027 Vaxcyte remains a 'Strong Buy' after robust phase 3 OPUS-1 results for VAX-31, demonstrating non-inferiority to Prevnar 20 and Capvaxive in adults. The company offers significant upside with multiple…
benzinga.com Crude Oil Edges Lower; Lamb Weston Shares Surge Following Upbeat Q1 Earnings U.S. stocks rose Tuesday: Dow +350 points, S&P 500 +0.86%. Lamb Weston jumped 12% on strong results; Arrivent plunged 58%.
defenseworld.net Vaxcyte (NASDAQ:PCVX) Sees Large Volume Increase Following Analyst Upgrade Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) shares saw unusually-strong trading volume on Tuesday after Needham and Company LLC raised their price target on the stock from $110.00 to $122.00.…
benzinga.com Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Gain as Scott Bessent Doubles Down on Iran Pressure— OPCH, PCVX, STZ in Focus (UPDATED) U.S. stock futures were higher on Tuesday, as the Dow Jones, S&P 500 and Nasdaq 100 indices rose, following Monday's higher close.
defenseworld.net Vaxcyte’s VAX-31 Meets All Primary Endpoints in Pivotal Phase III OPUS-1 Trial Vaxcyte (NASDAQ: PCVX) said its investigational 31-valent pneumococcal conjugate vaccine, VAX-31, met all pre-specified primary immunogenicity endpoints in the pivotal Phase III OPUS-1 trial in…
benzinga.com Goosehead Insurance, Decent Holding And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. stock futures rose, while Goosehead fell after a downgrade; NFT, Armada and other stocks also slid in premarket trading.
benzinga.com Why Option Care Health Shares Are Trading Higher By Around 24%; Here Are 20 Stocks Moving Premarket Option Care Health jumped 23.8% on reports McKesson and CD&R may acquire it; Freight Technologies led gainers, while NFT Ltd. led decliners.
benzinga.com Moderna, Vaxcyte and Novavax Are Trending After-Hours as Suspected Pneumonic Plague In Russia Stirs Anxiety Vaccine stocks are trending on Tuesday. Shares of Moderna Inc. (NASDAQ:MRNA), Vaxcyte Inc. (NASDAQ:PCVX) and Novavax Inc. (NASDAQ:NVAX) are moving in the after-hours session on Monday. Moderna rose…
marketbeat.com Vaxcyte's VAX-31 Meets All Primary Endpoints in Pivotal Phase III OPUS-1 Trial Vaxcyte NASDAQ: PCVX said its investigational 31-valent pneumococcal conjugate vaccine, VAX-31, met all pre-specified primary immunogenicity endpoints in the pivotal Phase III OPUS-1 trial in adults.
globenewswire.com Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes SAN CARLOS, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that it has commenced underwritten public offerings of…
seekingalpha.com Vaxcyte, Inc. (PCVX) Discusses Top Line Results From OPUS-1 Phase 3 Trial of VAX-31 Pneumococcal Vaccine Candidate Transcript Vaxcyte, Inc. (PCVX) Discusses Top Line Results From OPUS-1 Phase 3 Trial of VAX-31 Pneumococcal Vaccine Candidate Transcript
benzinga.com Needham Maintains Buy on Vaxcyte, Raises Price Target to $122 Needham analyst Joseph Stringer maintains Vaxcyte (NASDAQ:PCVX) with a Buy and raises the price target from $110 to $122.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers HeartBeam (NASDAQ:BEAT) stock moved upwards by 70.5% to $0.74 during Monday's regular session. The market value of their outstanding shares is at $24.4 million. PDS Biotechnology…
benzinga.com Dow Gains 100 Points; ISM Services PMI Falls In September U.S. stocks rose Monday: Dow +0.2%, S&P 500 +0.62%, Nasdaq +0.84%. Materials led; ISM services PMI slipped to 54.9. Oil fell 1%.
proactiveinvestors.com Vaxcyte shares surge on late-stage vaccine trial success Vaxcyte (NASDAQ:PCVX) shares surged 57% in morning trading on Monday after the biotechnology company said its experimental pneumococcal vaccine VAX-31 generated immune responses comparable to rival…
defenseworld.net Vaxcyte (NASDAQ:PCVX) Stock Sees Heavy Call Option Buying Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) saw unusually large options trading activity on Monday. Investors bought 2,615 call options on the stock. This represents an increase of approximately…
barrons.com Vaxcyte Stock Spikes 57% as Lead Vaccine Candidate Takes Aim at Pfizer and Merck Vaxcyte is poised to capture significant share of a $3 billion to $6 billion market following the latest trial results, Jefferies says.
defenseworld.net Vaxcyte (NASDAQ:PCVX) Reaches New 52-Week High – Here’s Why Shares of Vaxcyte, Inc. (NASDAQ: PCVX - Get Free Report) reached a new 52-week high on Monday. The company traded as high as $89.00 and last traded at $87.1950, with a volume of 1927060 shares…
benzinga.com RXO, Vaxcyte, PTC And Other Big Stocks Moving Higher On Monday U.S. stocks mixed as Dow falls 250+ points; RXO surges 23% on $5.8B C.H. Robinson deal, while Vaxcyte and PTC post major gains.
benzinga.com Vaxcyte Stock Hits New 52-Week High - Here's Why Vaxcyte Inc. (NASDAQ:PCVX) stock is surging on Monday on positive topline results from its pivotal Phase 3 OPUS-1 trial evaluating VAX-31, an investigational 31-valent pneumococcal conjugate vaccine.
benzinga.com Vaxcyte Stock Hits New 52-Week High - Here’s Why Vaxcyte announced positive Phase 3 OPUS-1 trial results for its VAX-31 vaccine candidate, setting the stage for an FDA BLA filing.
benzinga.com Guggenheim Maintains Buy on Vaxcyte, Raises Price Target to $125 Guggenheim analyst Seamus Fernandez maintains Vaxcyte (NASDAQ:PCVX) with a Buy and raises the price target from $116 to $125.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Apimeds Pharmaceuticals (AMEX:APUS) stock moved upwards by 76.7% to $5.69 during Monday's pre-market session. The market value of their outstanding shares is at $4.8 million. Alector…- benzinga.com Vaxcyte Says Topline Results From OPUS-1 Pivotal Adult Phase 3 Trial Of VAX-31, a 31-valent Pneumococcal Conjugate Vaccine Candidate, Met All Prespecified Primary Endpoints Across Age Groups Studied Compared To Prevnar 20 And/Or Capvaxive VAX-31 Met All Prespecified Primary Endpoints Across Age Groups Studied Compared to Prevnar 20 (PCV20) and/or Capvaxive (PCV21)Prespecified Co-Primary Immunogenicity Endpoints: In Adults 50 and…
globenewswire.com Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company's 31-Valent Pneumococcal Conjugate Vaccine Candidate VAX-31 Met All Prespecified Primary Endpoints Across Age Groups Studied Compared to Prevnar 20® (PCV20) and/or Capvaxive® (PCV21)
globenewswire.com Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company's 31-Valent Pneumococcal Conjugate Vaccine Candidate SAN CARLOS, Calif., Oct. 04, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced it will host a webcast and conference call tomorrow,…
benzinga.com Alphabet To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Monday Analysts raised targets for Vertex and Okta, while cutting targets for McDonald’s, AutoZone, Vaxcyte and Camping World.- benzinga.com B of A Securities Maintains Buy on Vaxcyte, Lowers Price Target to $130 B of A Securities analyst Jason Gerberry maintains Vaxcyte (NASDAQ:PCVX) with a Buy and lowers the price target from $133 to $130.
zacks.com 4 Biotech Stocks With Key Clinical Readouts Expected This Fall KOD, CLDX, RAPP and PCVX face key clinical readouts this fall that could influence their drug and vaccine pipelines.
benzinga.com Warren Buffett Disciple Seth Klarman Bets on Cruise Lines, Auto Parts, Amazon and Bill Ackman in Q2 Value investor Seth Klarman reveals his latest stock picks in a second quarter filing for hedge fund Baupost Group.
benzinga.com Vaxcyte Q2 EPS $(1.97) Beats $(2.22) Estimate Vaxcyte (NASDAQ:PCVX) reported quarterly losses of $(1.97) per share which beat the analyst consensus estimate of $(2.22) by 11.26 percent. This is a 61.48 percent decrease over losses of $(1.22) per…
benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Top 3 Health Care Stocks You'll Regret Missing In May The health care sector's most oversold stocks are a buying opportunity due to undervalued companies. RSI indicator shows potential for short-term gains.
benzinga.com Earnings Scheduled For May 6, 2026 
benzinga.com Vaxcyte Q1 EPS $(2.30) Misses $(1.82) Estimate Vaxcyte (NASDAQ:PCVX) reported quarterly losses of $(2.30) per share which missed the analyst consensus estimate of $(1.82) by 26.37 percent. This is a 121.15 percent decrease over losses of $(1.04)…
benzinga.com Vaxcyte Hits Enrollment Cap For Phase 3 Trials For VAX-31, A Pneumococcal Conjugate Vaccine Candidate Vaxcyte's next-generation 31-valent pneumococcal conjugate vaccine (PCV) candidate, for the prevention of invasive pneumococcal disease (IPD) and pneumonia in adults was finalized in consultation and…- benzinga.com Reported Earlier, Vaxcyte's VAX-31 Demonstrates Robust Immune Responses Across All 31 Serotypes In Lancet-Published Phase 1/2 Adult Study Versus Prevnar 20 Based on the Strength of Unprecedented Results from the Positive Phase 1/2 Study in Adults Aged 50 and Older, Vaxcyte Advanced VAX-31 High Dose into Comprehensive Phase 3 Adult Program; Topline Data…
benzinga.com Nvidia To Rally More Than 53%? Here Are 10 Top Analyst Forecasts For Thursday 
benzinga.com BTIG Maintains Buy on Vaxcyte, Raises Price Target to $89 BTIG analyst Thomas Shrader maintains Vaxcyte (NASDAQ:PCVX) with a Buy and raises the price target from $85 to $89.